Zuranolone is a small molecule commercialized by Biogen, with a leading Pre-Registration program in Post Partum Depression (Maternal Depression / Postnatal Depression). According to Globaldata, it is involved in 23 clinical trials, of which 14 were completed, 6 are ongoing, 1 is planned, and 2 were terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Zuranolone’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Zuranolone is expected to reach an annual total of $1.02 bn by 2032 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Zuranolone (SAGE-217, SAGE-NCE) is under development for the treatment of postpartum depression, bipolar disorder, major depressive disorder and generalized anxiety disorder. It is administered by the oral route. It is a new chemical entity (NCE) that targets GABAA receptor. SAGE-NCE is developed based on positive and negative allosteric modulator (PANAM) chemistry platform. It was also under development as an intravenous therapy for refractory status epilepticus (RSE) and as an oral therapy for orphan genetic epilepsy disorders, such as Dravet syndrome, Rett syndrome and Fragile X syndromes. The drug candidate was also under development for essential tremors, dyskinesias, insomnia and Parkinson’s disease.
Biogen is a biopharmaceutical company that discovers, develops, and delivers drugs and biosimilars for the treatment of various neurological and neurodegenerative diseases. The company’s marketed products include Avonex (interferon beta-1a), Vumerity (diroximel fumarate), Tysabri (natalizumab), Tecfidera (dimethyl fumarate), Fampyra (prolonged-release fampridine tablets), and Plegridy (peginterferon beta-1a) for the treatment of multiple sclerosis (MS); Spinraza (nusinersen) for spinal muscular atrophy (SMA); Aduhelm (aducanumab-avwa) for alzheimer’s disease, and Fumaderm (fumaric acid esters) for severe plaque psoriasis. It has several product candidates targeting various indications such as MS, Parkinson’s disease, Lupus, Depression, CNS and neuromuscular disorders, Amyotrophic Lateral Sclerosis, and Alzheimer’s disease. The company sells its products through direct sales force, marketing groups, and distributors in the Americas, Europe, Asia, and other territories. Biogen is headquartered in Cambridge, Massachusetts, the US.
The company reported revenues of (US Dollars) US$10,173.4 million for the fiscal year ended December 2022 (FY2022), a decrease of 7.4% over FY2021. The operating profit of the company was US$2,566.6 million in FY2022, compared to an operating profit of US$2,840.7 million in FY2021. The net profit of the company was US$3,046.9 million in FY2022, compared to a net profit of US$1,556.1 million in FY2021.
For a complete picture of Zuranolone’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.